TRANSDERMAL DELIVERY SYSTEM FOR DRIED PARTICULATE OR LYOPHILIZED MEDICATIONS

• US 20090137480A1
• Filed: 01/21/2009
• Published: 05/28/2009
• Est. Priority Date: 10/31/2002
• Status: Active Grant

• Current Assignee: Syneron Medical Limited (Syneron Incorporated)
• Original Assignee: Syneron Medical Limited (Syneron Incorporated)
• Inventors: Stern, Meir, Levin, Galit
• Granted Patent: US 8,133,505 B2
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61F 2013/00646 Medication patches, e.g. transcutaneous
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61K 9/703 characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
• CPC Class Codes: A61P 19/10 for osteoporosis

Abstract

The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of an agent that generates hydrophilic micro-channels, and a patch comprising a therapeutically active agent. The present invention is useful for transdermal delivery of hydrophilic agents, particularly of high molecular weight proteins.

Claims

1. A printed patch comprising a non-adhesive liner and a dried pharmaceutical composition comprising a calcitonin present on the non-adhesive liner, wherein the non-adhesive liner is made of a material that is not permeable to the calcitonin.

2. The printed patch according to claim 1, wherein the calcitonin is selected from the group consisting of salmon calcitonin, eel calcitonin, human calcitonin, rat calcitonin, sheep calcitonin, chicken calcitonin, ox calcitonin, and pig calcitonin.

3. The printed patch according to claim 2, wherein the salmon calcitonin is selected from the group consisting of salmon calcitonin I as set forth in SEQ ID NO:

1, salmon calcitonin II as set forth in SEQ ID NO;

2, salmon calcitonin III as set forth in SEQ ID NO;

3, salmon calcitonin IV as set forth in SEQ ID NO;

4, and salmon calcitonin V as set forth in SEQ ID NO;

5.

4. The printed patch according to claim 3, wherein the salmon calcitonin is salmon calcitonin I as set forth in SEQ ID NO:

1.

5. The printed patch according to claim 1, wherein the pharmaceutical composition further comprises a stabilizer.

6. The printed patch according to claim 5, wherein the stabilizer is a simple or complex carbohydrate.

7. The printed patch according to claim 6, wherein the simple or complex carbohydrate is selected from the group consisting of mannose, glucose, galactose, raffinose, cellobiose, gentiobiose, sucrose and trehalose.

8. The printed patch according to claim 1, wherein the pharmaceutical composition further comprises a buffering agent.

9. A method for treating a bone or cartilage disease or disorder in a subject comprising:

(a) generating a plurality of micro-channels in an area of the skin of a subject;

(b) affixing a printed patch according to claim 1 to the area of the skin of the subject where the plurality of micro-channels are present, the printed patch comprises a therapeutically effective amount of a calcitonin, thereby treating the bone or cartilage disease or disorder.

10. The method according to claim 9, wherein the calcitonin is selected from the group consisting of salmon calcitonin, eel calcitonin, human calcitonin, rat calcitonin, sheep calcitonin, chicken calcitonin, ox calcitonin, and pig calcitonin.

11. The method according to claim 10, wherein the salmon calcitonin is selected from the group consisting of salmon calcitonin I as set forth in SEQ ID NO:

1, salmon calcitonin II as set forth in SEQ ID NO;

2, salmon calcitonin III as set forth in SEQ ID NO;

3, salmon calcitonin IV as set forth in SEQ ID NO;

4, and salmon calcitonin V as set forth in SEQ ID NO;

5.

12. The method according to claim 11, wherein the salmon calcitonin is salmon calcitonin I as set forth in SEQ ID NO:

1.

13. The method according to claim 9, wherein the pharmaceutical composition further comprises a stabilizer.

14. The method according to claim 13, wherein the stabilizer is a simple or complex carbohydrate.

15. The method according to claim 14, wherein the simple or complex carbohydrate is selected from the group consisting of mannose, glucose, galactose, raffinose, cellobiose, gentiobiose, sucrose and trehalose.

16. The method according to claim 9, wherein the pharmaceutical composition further comprises a buffering agent.

17. The method according to claim 9, wherein the bone disease or disorder is selected from the group consisting of osteopenia and osteoporosis;

hypercalcemia;

Paget'"'"'s disease;

bone fracture, both vertebral and non-vertebral or bone deficiency;

Sudeck'"'"'s disease;

primary or secondary hyperparathyroidism;

periodontal disease or defect;

metastatic bone disorder;

osteolytic bone disease;

post-plastic bone surgery;

post-dental implantation; and

renal osteodystrophy.

18. The method according to claim 17, wherein the bone disease is osteoporosis.

19. The method according to claim 9, wherein the cartilage disease or disorder is selected from the group consisting of osteoarthritis;

rheumatoid arthritis;

septic arthritis;

post-prosthetic joint surgery; and

degenerative cartilage loss following traumatic joint injury.

20. The method according to claim 19, wherein the disease is osteoarthritis.

21. The method according to claim 9, wherein the subject is a human.